Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIGEN Vaccine for COVID-19
NCT04742842Phase 1Completed
- Sponsor
- University of Sydney
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of COVIGEN in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University of Sydney. Primary endpoints: Frequency of solicited local reactogenicity Adverse Events, Frequency of solicited systemic reactogenicity Adverse Events and 4 more. Started Jun 2021; status: completed.
02
Drugs
COVIGEN
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04742842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742842.